CA2860008C - Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators - Google Patents

Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators Download PDF

Info

Publication number
CA2860008C
CA2860008C CA2860008A CA2860008A CA2860008C CA 2860008 C CA2860008 C CA 2860008C CA 2860008 A CA2860008 A CA 2860008A CA 2860008 A CA2860008 A CA 2860008A CA 2860008 C CA2860008 C CA 2860008C
Authority
CA
Canada
Prior art keywords
mmol
title compound
tetraaza
hplc
uplc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2860008A
Other languages
English (en)
French (fr)
Other versions
CA2860008A1 (en
Inventor
Dominique Swinnen
Cyril Montagne
Vincent Pomel
Anna Quattropani
Jerome Molette
Patrick Gerber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP11195214.9A external-priority patent/EP2607364A1/en
Priority claimed from EP12171415.8A external-priority patent/EP2674434A1/en
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CA2860008A1 publication Critical patent/CA2860008A1/en
Application granted granted Critical
Publication of CA2860008C publication Critical patent/CA2860008C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA2860008A 2011-12-22 2012-11-30 Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators Active CA2860008C (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201161578931P 2011-12-22 2011-12-22
EP11195214.9 2011-12-22
EP11195214.9A EP2607364A1 (en) 2011-12-22 2011-12-22 Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators
US61/578,931 2011-12-22
US201261657978P 2012-06-11 2012-06-11
EP12171415.8A EP2674434A1 (en) 2012-06-11 2012-06-11 Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators
EP12171415.8 2012-06-11
US61/657,978 2012-06-11
PCT/EP2012/004968 WO2013091773A1 (en) 2011-12-22 2012-11-30 Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators

Publications (2)

Publication Number Publication Date
CA2860008A1 CA2860008A1 (en) 2013-06-27
CA2860008C true CA2860008C (en) 2020-11-10

Family

ID=48667735

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2860008A Active CA2860008C (en) 2011-12-22 2012-11-30 Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators

Country Status (8)

Country Link
US (1) US9403835B2 (enExample)
EP (1) EP2794608B1 (enExample)
JP (1) JP6112316B2 (enExample)
CN (1) CN104039789B (enExample)
AU (1) AU2012357169B2 (enExample)
CA (1) CA2860008C (enExample)
ES (1) ES2606839T3 (enExample)
WO (1) WO2013091773A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2813505A1 (en) * 2013-06-14 2014-12-17 Asceneuron SA Tetraaza-cyclopenta[a]indenyl derivatives
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
RU2702106C2 (ru) * 2014-08-26 2019-10-04 Астеллас Фарма Инк. Производное 2-аминотиазола или его соль
DK3256476T3 (en) * 2015-02-11 2019-03-11 Sunovion Pharmaceuticals Inc CONDENSED DIHYDRO-4H-PYRAZOLO [5,1-C] [1,4] OXAZINYL COMPOUNDS AND ANALOGS FOR TREATMENT OF CNS DISORDERS
US10822357B2 (en) * 2015-08-28 2020-11-03 Sekisui Medical Co., Ltd. Benzyl compound
EP3490607A4 (en) 2016-07-29 2020-04-08 Sunovion Pharmaceuticals Inc. COMPOUNDS AND COMPOSITIONS, AND USES THEREOF
CA3070993C (en) 2017-08-02 2025-05-20 Sunovion Pharmaceuticals Inc. ISOCHROMANE COMPOUNDS AND THEIR USES
FI3728207T3 (fi) 2017-12-21 2023-04-24 Ribon Therapeutics Inc Kinatsolinoneja parp14:n inhibiittoreina

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004525937A (ja) * 2001-03-27 2004-08-26 ニューロジェン コーポレイション （オキソ−ピラゾロ［１，５ａ］ピリミジン−２−イル）アルキル−カルボキサミド
AU2005315914B2 (en) * 2004-12-15 2011-03-03 F. Hoffmann-La Roche Ag Bi- and tricyclic substituted phenyl methanones as glycine transporter I (GlyT-1) inhibitors for the treatment of Alzheimer's disease
WO2008060488A1 (en) 2006-11-14 2008-05-22 Merck & Co., Inc. Tricyclic heteroaromatic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
EP2563126B1 (en) * 2010-04-30 2016-05-11 Merck Sharp & Dohme Corp. Heterocyclic quinolizine derived m1 receptor positive allosteric modulators
EP2813505A1 (en) * 2013-06-14 2014-12-17 Asceneuron SA Tetraaza-cyclopenta[a]indenyl derivatives

Also Published As

Publication number Publication date
JP2015502371A (ja) 2015-01-22
CA2860008A1 (en) 2013-06-27
US9403835B2 (en) 2016-08-02
AU2012357169A1 (en) 2014-08-07
AU2012357169B2 (en) 2017-03-30
JP6112316B2 (ja) 2017-04-12
WO2013091773A1 (en) 2013-06-27
ES2606839T3 (es) 2017-03-28
US20150018343A1 (en) 2015-01-15
EP2794608A1 (en) 2014-10-29
CN104039789B (zh) 2016-09-07
CN104039789A (zh) 2014-09-10
EP2794608B1 (en) 2016-09-14

Similar Documents

Publication Publication Date Title
CA2860008C (en) Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators
JP7682920B2 (ja) Ｉｌ－１７モジュレータとしてのジフルオロシクロヘキシル誘導体
CA3110474C (en) Highly active sting protein agonist compound
CA3163218A1 (en) Oxygen-containing heterocyclic compound, preparation method therefor and use thereof
AU2019228568B2 (en) Piperidinyl-3-(aryloxy)propanamides and propanoates
CA3066909A1 (en) Substituted bridged diazepane derivatives and use thereof as task-1 and task-3 inhibitors
CA3156982A1 (en) Arylmethylene heterocyclic compounds as kv1.3 potassium shaker channel blockers
CN114828963A (zh) 作为Kv1.3钾SHAKER通道阻滞剂的芳基杂二环化合物
JP2022530474A (ja) 複素環含有化合物、その使用及びそれを含む組成物
EP4499224A1 (en) N-(pyrrolidin-3-yl or piperidin-4-yl)acetamide derivatives
AU2025201400A1 (en) Glycyrrhetinic acid derivatives for treating hyperkalemia
CA3034796A1 (en) S1p1 agonist and application thereof
EP3008068B1 (en) Tetraaza-cyclopenta[a]indenyl derivatives
EP2607364A1 (en) Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators
EP2674434A1 (en) Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators
KR102902549B1 (ko) 고칼륨혈증 치료에 사용하기 위한 글리시레틴산 유도체
CN120752233A (zh) 取代的三环衍生物及其药物组合物和用途
KR20260004570A (ko) 고칼륨혈증 치료에 사용하기 위한 글리시레틴산 유도체
CA2972668A1 (en) Heterocyclylalkyne derivatives and their use as modulators of mglur5 receptors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20171128